Roche (ROG) investor relations material

Strategic priorities and business outlook

• Focus on innovation in diagnostics, clinical decision support tools, and comprehensive solutions across the care journey, aiming for mid to high single-digit sales growth and profit growth faster than sales.

• Expansion in high-growth segments: oncology, neurology, cardiometabolic, and infectious diseases, representing 60% of the global health burden, with targeted investments in early detection, therapy selection, and disease monitoring.

• Integration of digital and AI solutions, highlighted by acquisitions (PathAI, PathAl) and partnerships (Freenome, SAGA Diagnostics, NVIDIA, Recursion), to enhance diagnostic accuracy, efficiency, and support drug development.

• Sustainability initiatives include 100% renewable energy at all sites, significant reductions in water and greenhouse gas emissions, and expanded access to diagnostics in low-income countries.

• Continued investment in people and culture, with revamped incentive schemes, high-performing organization, and industry-leading employee engagement.

Product and technology pipeline

• Launch of AXELIOS, a next-generation DNA sequencing platform with blockbuster potential (CHF 1 billion+), targeting 100 placements in the first year and global market penetration.

• Expansion of the diagnostics menu with over 140 new tests planned across key disease areas, including neurology (pTau217, NfL), infectious diseases (IGRA TB), and cardiometabolic (CGM, Lp(a)).

• Core Lab innovations include the cobas Mass Spec system and cobas smart e immunoanalyzer, aiming to automate and expand testing capabilities for both high- and low-volume labs.

• Pathology Lab advancements focus on automation, digital pathology, and multiplexing, with the integration of AI-driven solutions and a growing menu of companion diagnostics.

• Near Patient Care portfolio strengthened by the rollout of Accu-Chek SmartGuide CGM, LumiraDx for decentralized testing, and new point-of-care platforms for emergency and primary care settings.

Financial guidance and growth drivers

• Diagnostics division targets mid to high single-digit sales growth, with profit growth outpacing sales, driven by new launches (AXELIOS, CGM, mass spec), operational efficiencies, and margin improvement.

• Core Lab segment growth revised to 3% CAGR due to China market headwinds, but offset by innovation and menu expansion.

• Oncology testing market expected to double in five years, with Foundation Medicine leveraging AXELIOS for improved turnaround and cost, and expanding decentralized and centralized testing models.

• Strategic acquisitions and partnerships positioned to drive growth in minimal residual disease, early cancer detection, and digital pathology.

• Ongoing advocacy for reimbursement reform in the U.S., with minimal expected impact from potential regulatory changes.